CRL — Clinical Research Labs
Back to catalog
PT-141 (Bremelanotide) 3ml vial label
Sexual HealthPurity 99.3%
Product profile

PT-141 (Bremelanotide)

Cyclic α-MSH analogue for sexual-function research.

99.3%
Purity
Lyophilized
Form
-20°C
Storage
Research Use Only. Not for human or veterinary consumption, diagnostic, or therapeutic use.

What it is

PT-141 (bremelanotide) is a cyclic heptapeptide analogue of α-MSH studied for central nervous-system control of sexual arousal.

Pathway Diagram

Mechanism of Action

CRL · MOA-01

Preferential MC4R agonism in CNS pathways governing sexual desire and arousal.

  1. Step 01
    Receptor Binding

    Peptide engages target receptor with high affinity.

  2. Step 02
    Signal Cascade

    Downstream intracellular pathways activate.

  3. Step 03
    Cellular Response

    Gene expression and protein synthesis shift.

  4. Step 04
    Observed Outcome

    Measurable change in the studied biomarker.

Primary TargetsHypoactive sexual desire researchMC4R signalingErectile pathway studies

Research highlights

Metabolite of Melanotan-II with preferential MC4R activity.
FDA-approved (Vyleesi) for premenopausal HSDD in women.
Acts centrally rather than via peripheral vasculature.
Investigated for both male and female sexual-function research.

Pharmacology snapshot

1025.2 Da
Molecular weight
~2.7 hours
Half-life
SC (research)
Route (research)
Sequence
Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH

Potential research applications

Hypoactive sexual desire research
MC4R signaling
Erectile pathway studies
Central arousal modeling

Case studies

Clinical24 weeks

RECONNECT phase 3 HSDD

Cohort: 1247 premenopausal women with HSDD

Pivotal phase 3 trial of bremelanotide for hypoactive sexual desire disorder.

Outcome

Significant improvements in desire and distress vs. placebo across pooled cohort.

Kingsberg et al., Obstet Gynecol 2019;134(5):899–908
ClinicalAcute

Intranasal PT-141 in ED

Cohort: Healthy men + ED patients

Early study of intranasal bremelanotide on erectile response.

Outcome

Dose-dependent erectile response in psychogenic and mild-moderate ED.

Diamond et al., Int J Impot Res 2004;16(1):51–59
PreclinicalMulti-week

Female CNS sexual function preclinical

Cohort: Rodent female sexual models

Preclinical CNS effects of bremelanotide on female sexual behavior.

Outcome

Activation of mPOA pathways underlying receptive sexual behavior.

Pfaus et al., J Sex Med 2007;4 Suppl 4:269–279
Handling Protocol

Storage Guidelines

CRL · STR-02

Lyophilized -20°C, light-protected.

Lyophilized
-20°C
Long-term, 24 months
Reconstituted
2–8°C
Refrigerated, 28 days
Light Exposure
Protect
Store in dark vial
Diluent
BAC Water
Sterile, 0.9% benzyl
Best practice — reconstitute with bacteriostatic water, swirl gently, do not shake.
Regulatory Notice

Research Disclaimer

CRL · REG-03
Research Use Only

Strictly for in-vitro laboratory and research investigations.

Not For Human Use

Not approved for diagnostic, therapeutic, or veterinary application.

Qualified Personnel

Handling restricted to licensed researchers and laboratory staff.

Warning — PT-141 (Bremelanotide) is supplied solely for legitimate laboratory research. Any administration to humans or animals is strictly prohibited and may violate federal, state, or local law. By purchasing, the researcher accepts full responsibility for safe handling, storage, and lawful use.

Document · CRL-REG-03Revision 2026.06 · Clinical Research Labs
Representative Literature

Citations & References

CRL · REF-04
  1. 01
    Kingsberg SA, Clayton AH, Portman D, et al. · 2019
    Bremelanotide for the treatment of hypoactive sexual desire disorder (RECONNECT)
    Obstet Gynecol. 134(5):899–908.
    DOI · 10.1097/AOG.0000000000003500PMID · 31599840
  2. 02
    Diamond LE, Earle DC, Rosen RC, et al. · 2004
    Double-blind, placebo-controlled evaluation of the safety, pharmacokinetic properties and pharmacodynamic effects of intranasal PT-141, a melanocortin receptor agonist, in healthy males and patients with mild-to-moderate erectile dysfunction
    Int J Impot Res. 16(1):51–59.
    DOI · 10.1038/sj.ijir.3901139PMID · 14963471
  3. 03
    Pfaus J, Giuliano F, Gelez H. · 2007
    Bremelanotide: an overview of preclinical CNS effects on female sexual function
    J Sex Med. 4 Suppl 4:269–279.
    DOI · 10.1111/j.1743-6109.2007.00610.xPMID · 17958612
References are representative of peer-reviewed literature and are provided for research context only.
Document · CRL-REF-04Revision 2026.06 · Clinical Research Labs